PH3_2017 - page 8

Ten new recommendations for more patient-centric innovation and properly assess
benefits of value added medicines, according to the new study “Value added Medicines:
time to adjust the HTA decision Frameworks”
The HealthTechnology Assessment (HTA) is a system
for assessing innovation in the healthcare systems of
European countries.
Though it has helped to achieve better pateient access
to therapies, the HTA system can be improved, at least
according to the new study “Value added Medicines:
time to adjust the HTA decision Frameworks” launched
in September by theValue Added Medicines group, a
sector group of Medicines For Europe.
The study, conducted by MondherToumi, Professor of
Public Health at Aix-MarseilleUniversity, highlights the
need for adjustments in HTA decision frameworks to
ensure that European patients can benefit from value
addedmedicines, that “
represent an opportunity for
increasing the cost-effectiveness of treatments or services
that may bring substantial value to individual patients
and society. However, the current European HTA decision
frameworks represent various challenges for the full value
recognition of these products, which need to be addressed.
Value added medicines are defined as “medicines based
on known molecules that address healthcare needs and
deliver relevant improvements for patients, healthcare
professionals and/or payers” (1). They represent an
opportunity for increasing the cost-effectiveness of
treatments or services that may bring substantial value
to individual patients and society (including citizens,
healthcare professionals, payers, etc).
The added value may be achieved through:
• medicine repositioning (to extendmedicine indication),
• medicine reformulation,
• medicine combination (medicine/medicine or
medicine/device or medicine/service).
The added value is benefited by both
patients
, in terms of:
• better efficacy, safety and/or tolerability profile,
• optimised route of administration and/or
convenience of use,
• access to new therapeutic uses of already existing
products covering unmet needs,
and
society
, in terms of:
• addressing a number of medicine-related
healthcare inefficiencies,
• enhancing healthcare system efficiency by
improving healthcare provision and organisation,
• contributing to sustainability of healthcare
systems through economic advantages.
However, says the study, the current European Health
TechnologyAssessment frameworks, depending on
the country, represent various challenges for full value
recognition of value added medicines. Several initiatives
undertaken at European level and involving HTA bodies,
regulators, academics, research organisations and the
pharmaceutical industry may contribute to ensuring
that the society receives all the potential benefits
associated with value added medicines.
The study underlines the importance of the eligibility
of value added medicines for HTA, whenever
requested, in order to demonstrate these relevant
improvements.
Ten key recommendations
Ten key recommendations are put forward in the report
to ensure that value added medicines can be rightfully
assessed by HTA decision frameworks in the future.
As for
research activities
:
1) there is a need to support the development of a
robust and reliable methodology to implement
multiple criteria decision analysis techniques
(MCDA) in HTA decision frameworks.
MCDAmethods require additional research and
shared guidelines for appropriate use to become
actionable. The benefits of value added medicines
on value dimensions such as patient preferences,
HTA: how can we improve it?
NEWS
6
focus on Pharma Packaging and Excipients
PHARMA HORIZON –
vol. 1(3) 2017
1,2,3,4,5,6,7 9,10,11,12,13,14,15,16,17,18,...68
Powered by FlippingBook